Summary:
Florida Pulmonary Research Institute is conducting a phase iii, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma.
Qualified Participants Must:
•
Have been diagnosed with Asthma for over 1 year
•
Only be on a rescue inhaler
•
Be 18 years of age or older
Qualified Participants May Receive:
Study medication, study related physician consultation, and compensation for time and travel.